Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study

BACKGROUND: Patients with a diagnosis of schizophrenia are at an increased risk for developing metabolic syndrome, which is associated with greater cardiovascular morbidity and mortality. Treatment with some commonly used antipsychotic medications may increase the risk of developing metabolic syndro...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattingly, Greg W., Haddad, Peter M., Tocco, Michael, Xu, Jane, Phillips, Debra, Pikalov, Andrei, Loebel, Antony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201608/
https://www.ncbi.nlm.nih.gov/pubmed/32370778
http://dx.doi.org/10.1186/s12888-020-02523-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201608/
https://www.ncbi.nlm.nih.gov/pubmed/32370778
http://dx.doi.org/10.1186/s12888-020-02523-1

Ejemplares similares